Futibatinib is an oral, selective, and irreversible small molecule inhibitor of the fibroblast growth factor receptor (FGFR) indicated for the treatment of adult patients with unresectable, locally advanced,… Read more
Futibatinib is an oral, selective, and irreversible small molecule inhibitor of the fibroblast growth factor receptor (FGFR) indicated for the treatment of adult patients with unresectable, locally advanced, or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements. Pharmaceutical laboratories utilize high-quality Futibatinib reference standards, including pharmacopeial and non-pharmacopeial impurities, to support rigorous analytical testing and method validation. These compounds are essential for accurate impurity profiling and quantitative analysis throughout the drug development lifecycle. Additionally, stable isotope labelled compounds of Futibatinib serve as critical internal standards in mass spectrometry-based assays, ensuring precise identification and quantification of the active pharmaceutical ingredient. Incorporating these reference materials into quality control protocols allows researchers to maintain compliance with regulatory standards and ensure the efficacy and safety of pharmaceutical products in complex biological matrices.